Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 6/2013

01-12-2013 | PHASE I STUDIES

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

Authors: S. F. Dent, K. A. Gelmon, K. N. Chi, D. J. Jonker, N. Wainman, C. A. Capier, E. X. Chen, J. F. Lyons, L. Seymour

Published in: Investigational New Drugs | Issue 6/2013

Login to get access

Summary

Purpose AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmacodynamic properties of AT9283. Patients and methods Patients with advanced, incurable solid tumors or non-Hodgkin’s lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. A 3 + 3 dose escalation design was used with a starting dose of 1.5 mg/m2/day. Pharmacokinetic samples were collected from all patients on cycle one, and pharmacodynamic samples were collected from 4 patients at the recommended phase II dose (RP2D). Results 35 patients were evaluable for toxicity and 32 were evaluable for response. AT9283 was well tolerated, with main toxicities being reversible dose-related fatigue, gastrointestinal disturbance, anemia, lymphocytopenia and neutropenia. The dose limiting toxicities were febrile neutropenia (two patients) and neutropenia with grade 3 infection (1 patient) at 47 mg/m2/day (established as the maximum tolerated dose). The RP2D was 40 mg/m2/day. Pharmacokinetic analyses showed AT9283 appeared to follow linear kinetics, with a mean elimination half-life of 8.2 h. Pharmacodynamic analyses showed no consistent or significant changes, but trends suggested evidence of AT9283 inhibition and anti-proliferative activity. One patient had partial response and four patients experienced RECIST stable disease (median 2.6 months). Conclusion In this study, AT9283 was well tolerated. The RP2D is 40 mg/m2/day on days 1, 8 of a 21-day cycle. Ongoing AT9283 trials will assess efficacy and safety in solid and haematological cancers.
Appendix
Available only for authorised users
Literature
1.
Adams RR, Carmena M, Earnshaw WC (2001) Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11:49–54CrossRefPubMed
2.
Carmena M, Earnshaw WC (2003) The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 4:842–854CrossRefPubMed
3.
Nigg EA (2001) Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2:21–32CrossRefPubMed
4.
Moore AS, Blagg J, Linardopoulos S, Pearson AD (2010) Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias. Leukemia 24:671–678CrossRefPubMed
5.
Qi W, Liu X, Cooke LS, Persky DO, Miller TP, Squires M et al (2012) AT9283, a novel aurora kinase inhibitor, suppresses tumour growth in aggressive B-cell lymphomas. Int J Cancer 130(12):2997–3005CrossRefPubMed
6.
Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y (2008) Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 14(14):4455–4462CrossRefPubMed
7.
Landen CN Jr, Lin YG, Immaneni A, Deavers MT, Merritt WM, Spannuth WA et al (2007) Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 13(14):4098–4104CrossRefPubMed
8.
Bischoff JR, Anderson L, Zhu Y, Mossie K, Ng L, Souza B et al (1998) A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 17(11):3052–3065PubMedCentralCrossRefPubMed
9.
Renshaw JS, Patnaik A, Gordon M, Beeram M, Fischer A, Gianella-Borradori A et al (2007) A phase I two arm trial of AS703569 (R763), an orally available aurora kinase inhibitor, in subjects with solid tumors; preliminary results. J Clin Oncol 25(suppl):622s, abstract 14130
10.
Gritsko TM, Coppola D, Paciga JE, Yang L, Sun M, Shelley SA et al (2003) Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. Clin Cancer Res 9(4):1420–1426PubMed
11.
Katayama H, Ota T, Jisaki F, Ueda Y, Tanaka T, Odashima S et al (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91(13):1160–1162CrossRefPubMed
12.
Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K et al (2003) Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 9(3):991–997PubMed
13.
Miyoshi Y, Iwao K, Egawa C, Noguchi S (2001) Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 92(3):370–373CrossRefPubMed
14.
Sakakura C, Hagiwara A, Yasuoka R, Fujita Y, Nakanishi M, Masuda K et al (2001) Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84(6):824–831PubMedCentralCrossRefPubMed
15.
Sen S, Zhou H, Zhang RD, Yoon DS, Vakar-Lopez F, Ito S et al (2002) Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst 94(17):1320–1329CrossRefPubMed
16.
Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J et al (2009) Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multi-targeted kinase inhibitor with potent Aurora kinase activity. J Med Chem 52(2):379–388CrossRefPubMed
17.
Curry J, Angove H, Fazal L, Lyons J, Reule M, Thompson N et al (2009) Aurora B kinase inhibition in mitosis: strategies for optimising the use of Aurora kinase inhibitors such as AT9283. Cell Cycle 8(12):1921–1929CrossRefPubMed
18.
Santo L, Hideshima T, Nelson EA et al (2009) AT9283, a small molecule multi-targeted kinase inhibitor induces antimyeloma activity via potent aurora kinase and STAT3 inhibition [abstract]. In: American Society Haematology Annual Meeting and Exposition, December 5–8, 2009, New Orleans, USA. Abstract 3883, Poster III-769
19.
Plummer ER, Calvert H, Arkenau H, Mallett KH, Squires M, Smith D et al (2008) A dose-escalation and pharmacodynamic study of AT9283 in patients with refractory solid tumours. J Clin Oncol 26(May 20 Suppl): 117s abstract 2520
20.
Foran JM, Ravandi F, O’Brien SM, Borthakur G, Rios M, Boone P et al (2008) Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor in patients with refractory leukemia. J Clin Oncol 27(155 Suppl):15s abstract 2566
21.
Kristeleit R, Calvert H, Arkenau H, Olmos D, Adam J, Plummer ER et al (2009) A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumours. J Clin Oncol 27(Suppl 15s): abstract 2566
22.
Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M et al (2012) A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 23(5):1307–1313CrossRefPubMed
23.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216CrossRefPubMed
24.
Walsby E, Walsh V, Pepper C, Burnett A, Mills K (2008) Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts. Haematologica 93(5):662–669CrossRefPubMed
25.
Linden MD, Torres FX, Kubus J, Zarbo RJ (1992) Clinical application of morphological and immunocytochemical assessments of cell proliferation. Am J Clin Pathol 97(5 Suppl 1):S4–S13PubMed
26.
Cuevas E, Jones D, Wright D (1993) Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 169(4):477–478CrossRefPubMed
27.
Dees EC, Infante JR, Cohen RB, O’Neil BH, Jones S, von Mehren M et al (2011) Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumours. Cancer Chemother Pharmacol 67(4):945–954PubMedCentralCrossRefPubMed
28.
Macarulla T, Cervantes A, Elez E, Rodriguez-Braun E, Baselga J, Rosello S et al (2010) Phase I study of the selective Aurora A Kinase Inhibitor MLN8054 in patients with advanced solid tumours: safety, pharmacokinetics, and pharmacodynamics. Mol Cancer Ther 9(10):2844–2852CrossRefPubMed
29.
Metadata
Title
NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies
Authors
S. F. Dent
K. A. Gelmon
K. N. Chi
D. J. Jonker
N. Wainman
C. A. Capier
E. X. Chen
J. F. Lyons
L. Seymour
Publication date
01-12-2013
Publisher
Springer US
Published in
Investigational New Drugs / Issue 6/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-013-0018-9

Other articles of this Issue 6/2013

Investigational New Drugs 6/2013 Go to the issue

PHASE II STUDIES

Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients

PHASE I STUDIES

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

PHASE II STUDIES

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide

SHORT REPORT

The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers

SHORT REPORT

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)

PHASE I STUDIES

A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits